This insight is necessary to advance clinical strategies for the treatment of obesity with improved GLP-1 analogs, with the hope of mitigating the nausea pervasive to current existing GLP-1–based pharmacotherapies. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.